These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. Roberti A, La Sala D, Cinti C. J Cell Physiol; 2006 Jun; 207(3):571-81. PubMed ID: 16250021 [Abstract] [Full Text] [Related]
8. Roots of imatinib resistance: a question of self-renewal? Burchert A. Drug Resist Updat; 2007 Jun; 10(4-5):152-61. PubMed ID: 17683977 [Abstract] [Full Text] [Related]
10. Epigenetic biomarkers for human cancer: the time is now. Mulero-Navarro S, Esteller M. Crit Rev Oncol Hematol; 2008 Oct; 68(1):1-11. PubMed ID: 18430583 [Abstract] [Full Text] [Related]
13. Defining the steps that lead to cancer: replicative telomere erosion, aneuploidy and an epigenetic maturation arrest of tissue stem cells. Stindl R. Med Hypotheses; 2008 Oct; 71(1):126-40. PubMed ID: 18294777 [Abstract] [Full Text] [Related]
14. Transcription factors and drug resistance. Kohno K, Uchiumi T, Niina I, Wakasugi T, Igarashi T, Momii Y, Yoshida T, Matsuo K, Miyamoto N, Izumi H. Eur J Cancer; 2005 Nov; 41(16):2577-86. PubMed ID: 16209921 [Abstract] [Full Text] [Related]
15. MicroRNAs. Fabbri M, Croce CM, Calin GA. Cancer J; 2008 Nov; 14(1):1-6. PubMed ID: 18303474 [Abstract] [Full Text] [Related]
16. Non-mammalian models for epigenetic analyses in cancer. Schaefer M, Meusburger M, Lyko F. Hum Mol Genet; 2007 Apr 15; 16 Spec No 1():R1-6. PubMed ID: 17613542 [Abstract] [Full Text] [Related]